Keefer, M C <br/><br/>
Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.  [electronic resource] 

 -  AIDS research and human retroviruses  May 1996 
 - 683-93 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0889-2229 
<br/><br/><label>Standard No.: </label>10.1089/aid.1996.12.683  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AIDS Vaccines--administration & dosage<br/>Adjuvants, Immunologic--administration & dosage<br/>Adolescent<br/>Adult<br/>Amino Acid Sequence<br/>Cells, Cultured<br/>Consumer Product Safety<br/>Dose-Response Relationship, Immunologic<br/>Double-Blind Method<br/>Female<br/>HIV Antibodies--blood<br/>HIV Envelope Protein gp120--immunology<br/>HIV Infections--immunology<br/>HIV-1--immunology<br/>Humans<br/>Leukocytes, Mononuclear--cytology<br/>Male<br/>Middle Aged<br/>Molecular Sequence Data<br/>Polysorbates--administration & dosage<br/>Squalene--administration & dosage<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Vaccines, Synthetic--administration & dosage